Victory Capital Management
LYRA

Victory Capital Management’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Victory Capital Management’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-957
Closed -$542K – 2530
2020
Q2 		$542K Buy
+957
New +$700K ﹤0.01% 1965

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Victory Capital Management's LYRA Position: Q3 2020 in Review

Victory Capital Management sold out of LYRA THERAPEUTICS INC (LYRA) in Q3 2020, closing a stake of 957 shares — an estimated $542K sold.

Victory Capital Management first reported a position in LYRA in Q2 2020 and held it in 1 quarter. The position peaked at $542K in Q2 2020. 40 funds tracked by Wall St. Rank hold LYRA as of Q3 2020.

  • Victory Capital Management reported no remaining LYRA THERAPEUTICS INC position as of Q3 2020 after selling out during the quarter.
  • Victory Capital Management sold 957 LYRA THERAPEUTICS INC shares in Q3 2020, an estimated $542K.
  • Victory Capital Management first reported a position in LYRA THERAPEUTICS INC in Q2 2020 and held it in 1 quarter.
  • Victory Capital Management's LYRA THERAPEUTICS INC position peaked at $542K in Q2 2020.
  • 40 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q3 2020.

Based on Victory Capital Management's 13F filing for Q3 2020, filed 9 Nov 2020.